ISM
specificAn indolent mast cell neoplasm characterized by systemic infiltration of skin and internal organs by aggregates of neoplastic mast cells. There is no evidence of mast cell leukemia or clonal hematologic malignancy. Clinically, there is no evidence of palpable hepatomegaly and splenomegaly, malabsorption syndrome, or pathologic fractures.
9
Centers
9
Active Trials
—
Cancer Funding
Top Centers for ISM(9)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 55.6 |
| 2 | NCI Comprehensive Active Research Program | 55.6 |
| 3 | Duke Cancer InstituteDurham, NC NCI Comprehensive Active Research Program | 55.6 |
| 4 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 55.6 |
| 5 | Dartmouth Cancer CenterLebanon, NH NCI Comprehensive Active Research Program | 55.6 |
| 6 | University of Illinois Cancer CenterChicago, IL Active Research Program | 55.6 |
| 7 | Boston University Cancer CenterBoston, MA Active Research Program | 55.6 |
| 8 | Cancer Center at IllinoisUrbana, IL Active Research Program | 55.6 |
| 9 | University of Cincinnati Cancer CenterCincinnati, OH Active Research Program | 55.6 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →